563 related articles for article (PubMed ID: 31571167)
1. Transporter-Mediated Drug-Drug Interactions and Their Significance.
Liu X
Adv Exp Med Biol; 2019; 1141():241-291. PubMed ID: 31571167
[TBL] [Abstract][Full Text] [Related]
2. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
Sasabe H; Shimokawa Y; Shibata M; Hashizume K; Hamasako Y; Ohzone Y; Kashiyama E; Umehara K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3497-508. PubMed ID: 27021329
[TBL] [Abstract][Full Text] [Related]
3. SLC Family Transporters.
Liu X
Adv Exp Med Biol; 2019; 1141():101-202. PubMed ID: 31571165
[TBL] [Abstract][Full Text] [Related]
4. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
5. Transporter-mediated drug-drug interactions.
Müller F; Fromm MF
Pharmacogenomics; 2011 Jul; 12(7):1017-37. PubMed ID: 21787191
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Toxicokinetics Roles of Membrane Transporters at Kidney Level.
Veiga-Matos J; Remião F; Motales A
J Pharm Pharm Sci; 2020; 23():333-356. PubMed ID: 32997956
[TBL] [Abstract][Full Text] [Related]
7. Species differences in drug transporters and implications for translating preclinical findings to humans.
Chu X; Bleasby K; Evers R
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):237-52. PubMed ID: 23256482
[TBL] [Abstract][Full Text] [Related]
8. Transporter-mediated Natural Product-Drug Interactions.
Bi Y; Wang X; Ding H; He F; Han L; Zhang Y
Planta Med; 2023 Feb; 89(2):119-133. PubMed ID: 35304735
[TBL] [Abstract][Full Text] [Related]
9. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
10. Renal Drug Transporters and Drug Interactions.
Ivanyuk A; Livio F; Biollaz J; Buclin T
Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
[TBL] [Abstract][Full Text] [Related]
11. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions.
Kindla J; Fromm MF; König J
Expert Opin Drug Metab Toxicol; 2009 May; 5(5):489-500. PubMed ID: 19416085
[TBL] [Abstract][Full Text] [Related]
12. [Expression and regulation of drug transporters in placenta].
Bai MR; Sun DL; Jiang HD; Zheng CH
Yao Xue Xue Bao; 2016 Jun; 51(6):879-85. PubMed ID: 29878741
[TBL] [Abstract][Full Text] [Related]
13. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
14. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
16.
Zhou S; Shu Y
Drug Metab Dispos; 2022 May; 50(9):1238-50. PubMed ID: 35644529
[TBL] [Abstract][Full Text] [Related]
17. Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.
Fujioka K; Fekry MI; Rumsey JM; Steiner T; Thompson D; Mousa SA
Clin Transl Sci; 2023 Jun; 16(6):987-1001. PubMed ID: 36967488
[TBL] [Abstract][Full Text] [Related]
18. Transporters and drug-drug interactions: important determinants of drug disposition and effects.
König J; Müller F; Fromm MF
Pharmacol Rev; 2013 Jul; 65(3):944-66. PubMed ID: 23686349
[TBL] [Abstract][Full Text] [Related]
19. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
Patel M; Taskar KS; Zamek-Gliszczynski MJ
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S23-39. PubMed ID: 27385177
[TBL] [Abstract][Full Text] [Related]
20. Enantioselective Drug Recognition by Drug Transporters.
Uwai Y
Molecules; 2018 Nov; 23(12):. PubMed ID: 30467304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
